News & Updates

Apobiologix, a division of Apotex Inc., expanded its product portfolio with the launch of a pre-filled autoinjector for Lapelga®, the company’s biosimilar pegfilgrastim that launched in Canada in 2019. Apobiologix, focused on the development of biosimilars for global markets, is the only biosimilar company to offer a pegfilgrastim autoinjector. The pre-filled syringe for Lapelga will continue to be available to patients.

Applications for the 3rd annual HOPE (Honouring Oncology Pharmacy Excellence) Awards in Pharmacy are now open!

Patients prescribed Fulphila have access to a multi-use and multi-patient copay program providing up to a maximum of 25% immediate financial assistance at pharmacy:

You are invited to attend a complimentary session on Applying Practical Strategies for the Treatment and Management of Patients with CLL.

OFD and DI 2022 take place on Saturday, October 22 and Sunday October 23, 2022 as a two day CCCEP accredited online learning event. Register now!

Have you ever done research and thought about publishing it but didn’t know how to get started?

Join us for a conversation about self leadership in pharmacy with Maria Anwar.

CAPhO Connections Podcast Series keeps the oncology pharmacy community informed on matters affecting you and updated on CAPhO’s news related to education, awards, advocacy and research. Whether it’s your morning commute to work, a walk in the park

Viatris Inc. announced that Abevmy® is now available in Canada. Abevmy, is a biosimilar to Roche’s Avastin® (bevacizumab) and has been authorized for use by Health Canada across four oncology indications.

Many pharmacist-led and CAPhO-supported research initiatives are contributing significantly to advancing cancer care in Canada.

A needs assessment on the management of chronic lymphocytic leukemia (CLL) developed by a multidisciplinary committee of fellow healthcare providers is available!

Can you identify hazardous drug contamination in less than 10 minutes? BD® HD Check is an easy-to-use system to protect your facility from the risk of hazardous drug exposure.